frozen snapshot — 2026-08-04 · see today →
more minds
Reshma Kewalramani

What's on Reshma Kewalramani's mind?

read fresh this morning at 6
28%24%17%12%19%
Q2 results and raised 2026 guidance 28% · newThe $10B Crinetics acquisition 24% · newIgA nephropathy FDA verdict 17% · newLife after the CF franchise 12% · neweverything else 19%
#1
Vertex Beats, Then Raises the Bar on Itself

Strong second-quarter results, and 2026 revenue guidance goes up rather than sideways.

Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal

The Business Journals · 2026-08-04
our translation

raising guidance in august is a promise you have to keep in february. she'd rather buy the credibility now than sit on the cushion.

new — Q2 2026 results posted todayvery sure · 2 sources
#2
Ten Billion Dollars, and a CEO Explaining Why
new — CEO touted deal on Q2 callpretty sure · 1 source
#3
The IgAN Clock Is Running
new — FDA verdict looms in IgANpretty sure · 1 source
#4
Proving Vertex Is More Than One Disease
new — Renal filing plus endocrine M&Ahonestly, a hunch · 2 sources
tuesday, august 4
Field the analyst questions on why guidance went up(reported)
Have a crisp answer ready for 'why $10 billion for Crinetics'(reported)
Pressure-test IgAN launch readiness before the FDA date(reported)
Read the competitor IgAN data yourself, not the summary deck(safe bet)

rebuilt from the public schedule, pool reports & old habits — the rest is educated guessing

The source

Vertex posts strong 2nd-qtr 2026 results

news.google.com · 2026-08-04

every line on the pad traces to something public — tap to see it